United Therapeutics Corp
UTHR Real Time Price USDRecent trades of UTHR by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in UTHR holdings by institutional investors
Quarterly net insider trading by UTHR's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$20,000 Oct 19, 2025 Issue: None
-
$40,000 Jan 19, 2010 Issue: Pharmacy Defense Homeland Security Science/Technology
-
$50,000 Oct 19, 2009 Issue: Pharmacy Defense Homeland Security Science/Technology
-
$40,000 Jul 20, 2009 Issue: Science/Technology Homeland Security Defense Pharmacy
-
$40,000 Apr 15, 2009 Issue: Science/Technology Pharmacy Defense Homeland Security
-
$40,000 Jan 16, 2009 Issue: Defense Pharmacy Homeland Security Science/Technology
UTHR Estimated quarterly lobbying spending
UTHR Revenue by Segment or Geography
New UTHR patent grants
-
Patent Title: Automated bioreactor system, system for automatically implementing protocol for decellularizing organ, and waste decontamination system Nov. 04, 2025
-
Patent Title: Salts of treprostinil Jun. 05, 2018
-
Patent Title: Compounds and methods for delivery of prostacyclin analogs Jan. 30, 2018
-
Patent Title: Solid forms of treprostinil Nov. 21, 2017
-
Patent Title: Process for making beraprost Sep. 19, 2017
-
Patent Title: Controlled release pharmaceutical formulations Sep. 12, 2017
-
Patent Title: Parenteral formulations of treprostinil Jul. 25, 2017
-
Patent Title: Salts of treprostinil Jul. 11, 2017
-
Patent Title: Compounds and methods for delivery of prostacyclin analogs Apr. 18, 2017
-
Patent Title: Synthesis of intermediate for treprostinil production Apr. 04, 2017
-
Patent Title: Process to prepare treprostinil, the active ingredient in remodulin® Mar. 28, 2017
-
Patent Title: Process to prepare treprostinil, the active ingredient in remodulin® Mar. 14, 2017
-
Patent Title: Synthesis of intermediates for producing prostacyclin derivatives Mar. 14, 2017
-
Patent Title: Compounds and methods for delivery of prostacyclin analogs Aug. 23, 2016
-
Patent Title: Method of identifying therapies for pulmonary hypertension Jul. 12, 2016
-
Patent Title: Treprostinil administration by inhalation Jun. 07, 2016
-
Patent Title: Treprostinil administration by inhalation May. 17, 2016
-
Patent Title: Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same May. 03, 2016
-
Patent Title: Compounds and methods for delivery of prostacyclin analogs Mar. 08, 2016
-
Patent Title: Compounds and methods for delivery of prostacyclin analogs Dec. 01, 2015
-
Patent Title: Process to prepare treprostinil, the active ingredient in remodulin® Oct. 13, 2015
-
Patent Title: Dosage inhaler Oct. 13, 2015
-
Patent Title: Compounds and methods for delivery of prostacyclin analogs Jun. 09, 2015
-
Patent Title: Iminosugars and methods of treating viral diseases Jun. 02, 2015
-
Patent Title: Treatment for pulmonary hypertension Mar. 03, 2015
-
Patent Title: Treprostinil production Jan. 27, 2015
-
Patent Title: Use of treprostinil to treat and prevent ischemic lesions Jul. 01, 2014
-
Patent Title: Process to prepare treprostinil Jun. 10, 2014
-
Patent Title: Iminosugars and methods of treating togaviral diseases Jun. 10, 2014
-
Patent Title: Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same Feb. 25, 2014
-
Patent Title: Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same Feb. 18, 2014
-
Patent Title: Nebulized liposomes for the pulmonary application of drug compounds Feb. 18, 2014
-
Patent Title: Treatment for pulmonary hypertension Dec. 17, 2013
-
Patent Title: Use of treprostinil to treat neuropathic diabetic foot ulcers Oct. 22, 2013
-
Patent Title: Compounds and methods for delivery of prostacyclin analogs Sep. 17, 2013
-
Patent Title: Process to prepare treprostinil, the active ingredient in remodulin® Jul. 30, 2013
-
Patent Title: Treprostinil production Jul. 09, 2013
-
Patent Title: Synthesis of intermediate for treprostinil production Jun. 11, 2013
-
Patent Title: Combinatorial library approach to iminocyclitols with biological activity May. 21, 2013
-
Patent Title: Iminosugars and methods of treating bunyaviral and togaviral diseases Apr. 23, 2013
-
Patent Title: Compounds and methods for delivery of prostacyclin analogs Apr. 02, 2013
-
Patent Title: Iminosugars and methods of treating bunyaviral and togaviral diseases Feb. 05, 2013
-
Patent Title: Treprostinil formulation Jan. 08, 2013
-
Patent Title: Solid formulations of prostacyclin analogs Jan. 08, 2013
-
Patent Title: Compounds and methods for delivery of prostacyclin analogs Aug. 28, 2012
-
Patent Title: Process to prepare treprostinil, the active ingredient in remodulin Aug. 14, 2012
-
Patent Title: Compounds and methods for delivery of prostacyclin analogs Jul. 31, 2012
-
Patent Title: Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same Aug. 16, 2011
-
Patent Title: Use of treprostinil to treat neuropathic diabetic foot ulcers Feb. 01, 2011
-
Patent Title: Cooperative processing with mobile monitoring device and computer system May. 11, 2010
Federal grants, loans, and purchases
- $14,989 2025-09-24 00:00:00 Agency: Department of Veterans Affairs
- $16,745 2025-09-23 00:00:00 Agency: Department of Veterans Affairs
- $16,514 2025-09-23 00:00:00 Agency: Department of Veterans Affairs
- $14,989 2025-08-27 00:00:00 Agency: Department of Veterans Affairs
- $16,514 2025-08-21 00:00:00 Agency: Department of Veterans Affairs
- $16,525 2025-08-13 00:00:00 Agency: Department of Veterans Affairs
- $14,989 2025-08-11 00:00:00 Agency: Department of Veterans Affairs
- $14,989 2025-08-06 00:00:00 Agency: Department of Veterans Affairs
- $16,514 2025-08-03 00:00:00 Agency: Department of Veterans Affairs
- $37,233 2025-07-29 00:00:00 Agency: Department of Justice
- $43,440 2025-07-29 00:00:00 Agency: Department of Justice
- $37,233 2025-07-25 00:00:00 Agency: Department of Justice
- $14,989 2025-07-10 00:00:00 Agency: Department of Veterans Affairs
- $14,989 2025-07-02 00:00:00 Agency: Department of Veterans Affairs
- $16,514 2025-07-02 00:00:00 Agency: Department of Veterans Affairs
- $12,367 2025-06-18 00:00:00 Agency: Department of Justice
- $14,989 2025-06-13 00:00:00 Agency: Department of Veterans Affairs
- $16,514 2025-06-05 00:00:00 Agency: Department of Veterans Affairs
- $14,989 2025-06-04 00:00:00 Agency: Department of Veterans Affairs
- $6,331 2025-06-02 00:00:00 Agency: Department of Justice
- $14,989 2025-05-13 00:00:00 Agency: Department of Veterans Affairs
- $16,514 2025-04-29 00:00:00 Agency: Department of Veterans Affairs
- $14,989 2025-04-29 00:00:00 Agency: Department of Veterans Affairs
- $14,989 2025-04-15 00:00:00 Agency: Department of Veterans Affairs
- $0 2025-04-09 00:00:00 Agency: Department of Veterans Affairs
- $16,514 2025-04-03 00:00:00 Agency: Department of Veterans Affairs
- $14,989 2025-04-03 00:00:00 Agency: Department of Veterans Affairs
- $14,989 2025-03-19 00:00:00 Agency: Department of Veterans Affairs
- $14,989 2025-03-12 00:00:00 Agency: Department of Veterans Affairs
- $16,514 2025-03-11 00:00:00 Agency: Department of Veterans Affairs
- $14,989 2025-02-25 00:00:00 Agency: Department of Veterans Affairs
- $14,989 2025-02-07 00:00:00 Agency: Department of Veterans Affairs
- $16,745 2025-02-07 00:00:00 Agency: Department of Veterans Affairs
- $14,989 2025-02-07 00:00:00 Agency: Department of Veterans Affairs
- $16,514 2025-01-31 00:00:00 Agency: Department of Veterans Affairs
- $89,934 2025-01-21 00:00:00 Agency: Department of Veterans Affairs
- $14,989 2025-01-14 00:00:00 Agency: Department of Veterans Affairs
- $14,989 2025-01-14 00:00:00 Agency: Department of Veterans Affairs
- $16,514 2025-01-07 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-12-19 00:00:00 Agency: Department of Veterans Affairs
- $16,032 2024-12-10 00:00:00 Agency: Department of Veterans Affairs
- $16,392 2024-12-10 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-11-25 00:00:00 Agency: Department of Veterans Affairs
- $16,032 2024-11-13 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-11-07 00:00:00 Agency: Department of Veterans Affairs
- $16,032 2024-10-25 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-10-15 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-10-10 00:00:00 Agency: Department of Veterans Affairs
- $88,162 2024-10-08 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-09-25 00:00:00 Agency: Department of Veterans Affairs
Estimated quarterly amount awarded to UTHR from public contracts
Recent insights relating to UTHR
Recent picks made for UTHR stock on CNBC
ETFs with the largest estimated holdings in UTHR
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $UTHR stock a Buy, Sell, or Hold?
- What is the price target for $UTHR stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $UTHR stock?
- Who owns the most shares of $UTHR stock?
- What funds own $UTHR stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view UTHR Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
- Address Silver Spring, MD
- Market Cap 20.4 billion
- Employees 1,305
- Industrial Classification Pharmaceutical Preparations